Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
暂无分享,去创建一个
R. Pazdur | J. Gobburu | M. Rothmann | J. Duan | Martin H. Cohen | Atiqur Rahman | Gang Chen | Ann Staten | John R. Johnson | G. Williams | K. Benson | J. Leighton | S. K. Kim | Rebecca L. Wood | K. U | Mark Rothmann | M. Cohen
[1] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[2] J. Melo,et al. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[3] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[4] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[5] R. Kurzrock,et al. The BCR gene and philadelphia chromosome-positive leukemogenesis. , 2001, Cancer research.
[6] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[7] G. Bancroft,et al. Early Nonspecific Immune Responses and Immunity to Blood-Stage Nonlethal Plasmodium yoelii Malaria , 2000, Infection and Immunity.
[8] S. Woolf,et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. , 1999, Blood.
[9] Z. Estrov,et al. The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.
[10] C Chastang,et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. , 1997, The New England journal of medicine.
[11] H. Kantarjian,et al. Treatment of Chronic Myelogenous Leukemia: Current Status and Investigational Options , 1996 .
[12] R Ohno,et al. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. , 1995, Blood.
[13] S. Richards,et al. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.
[14] A. Bernstein,et al. Expression of Xkl-1, a Xenopus gene related to mammalian c-kit, in dorsal embryonic tissue , 1995, Mechanisms of Development.
[15] H. Heimpel,et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. , 1994, Blood.
[16] Sante Tura,et al. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. , 1994, The New England journal of medicine.
[17] E. Huang,et al. The expression pattern of the c-kit ligand in gonads of mice supports a role for the c-kit receptor in oocyte growth and in proliferation of spermatogonia. , 1993, Developmental biology.
[18] E. Estey,et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] O. Witte,et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.
[20] G. Daley,et al. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. , 1990, Science.
[21] H. Kantarjian,et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. , 1987, The American journal of medicine.
[22] T. Papayannopoulou,et al. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. , 1977, The American journal of medicine.
[23] S. Gartler,et al. Clonal origin of chronic myelocytic leukemia in man. , 1967, Proceedings of the National Academy of Sciences of the United States of America.
[24] B. Druker,et al. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. , 2000, The Journal of clinical investigation.
[25] A. Hagemeijer,et al. Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group. , 1998, Blood.